QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
December 02 2021 - 12:10AM
Business Wire
- Easy-to-use workflow can detect T-cell response early in the
course of COVID-19 infection or following vaccination
- Detection of T-cells can provide vital insights that
completes the picture of SARS-CoV-2 immune response – beyond
serology alone
- Cell-mediated immunity can also be assessed in individuals
who have been vaccinated
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA)
announced today the CE marking of its QuantiFERON® SARS-CoV-2 assay
that measures T-cell responses to SARS-CoV-2 and aids in the
assessment of immunity in individuals who have received COVID-19
vaccination.
COVID-19 vaccines stimulate the body to produce antibodies and
activate T-cells to fight a SARS-CoV-2 infection. Serology tests,
which measure the antibodies, often generate positive test results
after vaccination but are unable to assess cellular responses. The
QuantiFERON® SARS-CoV-2 assay detects CD4+ and CD8+ T-cell
responses, thereby enabling a much more comprehensive assessment of
immunity generated by COVID-19 vaccines.
The QuantiFERON® SARS-CoV-2 assay is based on QIAGEN’s
QuantiFERON® interferon gamma release technology, which is globally
recognized as an easy-to-use T-cell assay that employs whole blood
and – unlike other T-cell assays – does not require the
purification of lymphocytes for T-cell measurement.
“T-cells provide valuable insights into our immune system’s
response to COVID-19,” said Jean-Pascal Viola, Senior Vice
President and Head of the Molecular Diagnostics Business Area at
QIAGEN. “The more we know about this epidemic, the better equipped
the world will be to address this threat that will stay with us,”
he said. “We are excited about our QuantiFERON technology enabling
the assessment of immune responses that are crucial for the
prevention and management of the disease.”
T-cell response to SARS-CoV-2 declines much more slowly than
antibody response and may indicate how severe the course of an
illness triggered by SARS-CoV-2 will be in infected patients, and
how immune those are who have recovered many months – possibly even
years – after having been infected.
Further information on the product can be found at here.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of September
30, 2021, QIAGEN employed approximately 6,000 people in over 35
locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Category: Corporate
Source: QIAGEN N.V.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211201006190/en/
QIAGEN Investor Relations John Gilardi, +49 2103
29 11711 Phoebe Loh, +49 2103 29 11457 e-mail: ir@QIAGEN.com
Public Relations Thomas Theuringer, +49 2103 29 11826
e-mail: pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024